Alexion to Acquire Wilson Therapeutics for $855M

Alexion Pharmaceuticals plans to shell out $855 million to acquire Wilson Therapeutics, the companies said today, in a deal that would add its Phase III candidate for the rare genetic liver disorder and company namesake Wilson disease to the buyer’s shifting pipeline.Wilson Therapeutics is developing WTX101 (bis-choline tetrathiomolybdate), a first-in-class oral copper-protein binding agent designed to access and bind copper from serum and promote its removal from the liver. In November 20